Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

M7824 in Subjects With HPV Associated Malignancies

Trial Profile

M7824 in Subjects With HPV Associated Malignancies

Phase of Trial: Phase II

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs MSB 0011359C (Primary)
  • Indications Anal cancer; Cervical cancer; Head and neck cancer; Neuroendocrine carcinoma; Oropharyngeal cancer; Penile cancer; Rectal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 30 Aug 2018 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
    • 04 Jun 2018 According to a Merck KGaA media release, data (n=8) from the expansion cohort of the study were presented at the American Society of Clinical Oncology (ASCO) 2018, in collaboration with NCI.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top